Recombinant human interleukin-11 (rhIL-11) reduces the clinical signs and histological lesions of inflammatory bowel disease (IBD) in transgenic rats expressing the human major histocompatability complex (MHC) class I allele, HLA-B27. To elucidate the pharmacogenomic effects of rhIL-11 in this model, we examined the global gene expression pattern in inflamed colonic tissue before and following rhIL-11 treatment using oligonucleotide microarrays. In total, 175 disease-related genes were identified. Increased expression of genes involved in antigen presentation, cell death and inflammation, and decreased expression of metabolic genes was associated with disease. A total of 27 disease-related genes returned to normal expression levels following rhIL-11 treatment including the MHC class II gene RT1-DMb. rhIL-11 induced the expression of four intestinal epithelial growth factors. These gene expression patterns indicate that treatment of inflammatory bowel disease with rhIL-11 affects class II antigen processing and colonic epithelial cell proliferation and metabolism.
INTRODUCTION
The ability to quantitate global expression profiles using oligonucleotide microarrays in animal models of disease gives the opportunity to undertake pre-clinical pharmacogenomic studies to elucidate the effects of drug treatment on disease pathogenesis and to identify genes that are components of the disease mechanism. In addition, global expression profiles can be obtained following treatment with investigational drugs to identify expression changes modulated by drug treatment that can be correlated with amelioration of disease or adverse effects. Such genes may prove to be sensitive markers of drug activity that can be applied to human clinical trials or serve as potential targets for drug development programs. With the use of oligonucleotide arrays, studies are not limited to detecting a small number of genes pre-selected by a previous paradigm of disease or drug action but allow a global analysis of thousands of genes, perhaps leading to the identification of novel pathways.
The HLA-B27 transgenic rat co-expressing the human major histocompatability class I allele HLA-B27 and b2-microglobulin develops T-cell-dependent chronic multi-organ inflammatory disease including inflammatory bowel disease (IBD), reminiscent of human B27-associated spondyloarthropathies. 1 These animals develop spontaneous ileitis and colitis and exhibit lesions of the gastrointestinal tract suggesting they may serve as a model for Crohn's disease. Treatment of HLA-B27 rats with established colonic disease with recombinant human interleukin-11 (rhIL-11) ameliorated disease as measured by stool character and gross and histologic colonic lesion scores. 2 In a previous study, we showed that amelioration of disease by rhIL-11 correlated with decreased levels of molecular markers of inflammation in the colon, including reduced expression of multiple proinflammatory genes, reduced levels of myeloperoxidase activity, improvement in colonic lesions and a return to normal stool character. 3 In addition, spleen cells taken from rhIL-11-treated animals produced less inflammatory cytokines upon anti-CD3 antibody activation in vitro than cells derived from control animals, suggestive of rhIL-11-mediated effects on T cells or antigen presentation.
rhIL-11 is a pleiotropic cytokine with anti-inflammatory activity (reviewed in Schwertschlag et al 4 ) . rhIL-11 inhibits the production of pro-inflammatory mediators including TNF-a, IL-1b, and nitric oxide from activated macrophages 5, 6 through its ability to inhibit the nuclear translocation of the transcription factor NFkB. 7 In various animal models, rhIL-11 reduced the levels of TNF-a expression in the serum, 5 lung, and in alveolar 8 and intestinal macrophages. 9 In addition to its effects on macrophages, rhIL-11 has been shown to promote T cell polarization towards the Th2 phenotype directly by effects on T cells in vitro 10 and in a murine model of graft-vs-host disease. 11, 12 Recently, rhIL-11 has also been suggested to induce a Th2 T-cell phenotype in human psoriatic lesional tissue. 13 rhIL-11 also has effects on cells of the gastrointestinal epithelium. rhIL-11 directly interacts with intestinal epithelial cells in vitro.
14 In various animal models, treatment with rhIL-11 is associated with maintenance of the integrity of the gastrointestinal epithelium. In a murine model of severe cytoablative therapy, rhIL-11 treatment increased survival and was associated with proliferation and decreased apoptosis of intestinal epithelium crypt cells. 15 Similarly, in a murine model of massive small bowel resection, rhIL-11 was shown to have a trophic effect on small intestinal enterocytes, causing cell proliferation and increased mucosal thickness. 16 Based upon these activities, rhIL-11 is currently being evaluated for the treatment of Crohn's disease. 17 In the present study, we have extended our analysis of the molecular effects of rhIL-11 in the HLA-B27 rat. The Affymetrix Rat RG-U34A GeneChip s , representing about 8800 rat transcripts, was used to generate a global expression profile of the colons of HLA-B27 rats treated with rhIL-11 and compared to the colons of untreated HLA-B27 rats and Fischer 344 wild-type controls. This expression profiling experiment has identified 175 genes whose expression levels are changed in the diseased colon compared to non-diseased tissue and has identified genes that are responsive to rhIL-11 treatment. These results suggest possible pathways for the pathogenesis of IBD as well as the molecular basis of rhIL-11 efficacy in this animal model of IBD.
RESULTS

Identification of Disease-Related Gene Expression
To identify disease-related genes that are differentially expressed in the inflamed colon of the HLA-B27 rat model of IBD, we compared the gene expression profile of RNA isolated from the diseased colon of HLA-B27 rats with that of the non-diseased colon of the Fischer 344 rat. The expression profile of five HLA-B27 rat colons and five Fisher 344 colons was determined using Affymetrix Rat RG-U34A GeneChips s . Tissues from each animal were hybridized individually and were not pooled. The analysis software (EPIKS Explorer, Genetics Institute) yielded an absolute frequency value and a present, absent or marginal detection call for each gene. The data from individual animals were reduced according to criteria set forth in the Method section. In total, 175 genes were identified as differentially expressed in the diseased colon ( Table 1 ). The majority of gene expression level changes were at the magnitude of 2.4-5.0-fold. By far the most robust differential gene expression changes occurred in genes involved in protein, lipid and carbohydrate metabolism that were down-regulated in the diseased colon ( Figure 1 ). A total of 12 genes were upregulated higher than 5.0-fold compared to the nondiseased colon while 36 genes were down-regulated greater than 5-fold in the diseased colon. The highest change observed in the up-regulated gene set was a 38.2-fold induction of the pancreatitis-associated protein 1 (Pap1) gene. In comparison, 11 genes were down-regulated greater that 40-fold with the greatest reduction represented by amylase 1 (Amy1) at 126.9-fold.
Using the gene annotation method outlined in the Method section, we categorized the 175 disease-related genes into functional groups. This analysis clustered the diseaseassociated genes into 22 functional classifications (Table 1) . Genes associated with antigen processing and presentations were up-regulated in disease (group 1, Table 1 ). These genes include major histocompatibility complex (MHC) classes I and II molecules, MHC class II-associated invariant chain, proteosome subunits, and antigen transporter polypeptides. As expected, genes involved in an inflammatory response were also up-regulated in the diseased colon (group 2, Table  1 ). These included genes encoding interferon regulatory factors, chemokines, complement proteins and immunoglobin as well as signal transduction and transcription factor proteins associated with an inflammatory response (Stat1 and NfKb1, groups 6 and 5, respectively, Table 1 ). Also, genes encoding T-cell receptors (group 7, Table 1 ) were upregulated in the HLA-B27 rat colon, which supports the defined role of T cells being the pathological mediator of the disease in this animal model. 18 Genes associated with cell death or apoptosis were upregulated in diseased colonic tissue (Figure 1 ). This gene set includes caspase family members, Bak, Casp1, Casp7 and granzyme b (group 8, Table 1 ). Genes associated with the development and maintenance of cellular and structural components of the gastrointestinal mucosa were modulated in diseased tissue. Genes contained within each of these groups were both up-and down-regulated and included Table 1 ).
The most noteworthy changes in gene expression were seen in genes encoding metabolic enzymes (Figure 1 ). These metabolic genes were mostly down-regulated in disease and are associated with lipid (group 11, Genes are listed according to the functional catagorization as outlined in the experimental methods. The Unigene symbol representing each gene is listed along with the unique GeneBank accession number identifying the sequence. Fold change (Fold D) value represents the average change in expression level in the inflamed colon of the HLA-B27 rat when compared to their expression levels in the non-inflamed Fischer 344 rat colon. Significance was determined by a Student's t-test and the resultant P values are shown.
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Pharmacogenomic analysis of rhIL-11 treatment groups are involved in the metabolism of dietary steroids and fats. Only three genes out of the 36 associated with metabolism of dietary substrates are up-regulated in disease ( Figure 1 ). These genes include Pla2g2a (platelet phospholipase A2, group 11, Table 1 ), Pfkp (phosphofructokinase C) and Hk2 (hexokinase 2) (group 13, Table 1 ). Hk2 and Pfkp are the only two genes of the carbohydrate metabolism group that are up-regulated in disease (group 13, Table 1 ). All the proteins encoded by the metabolic enzymes noted above are secreted enzymes that must be packaged into secretory vesicles prior to export from the cell. In our analysis of diseased tissue, we saw a concomitant decrease in the expression of genes encoding integral membrane proteins of secretory (Sip9 19, 20 and GP-2 21, 22 ) and endocytic vesicles (Stx7 23 , group 10, Table 1 ). We also detected a significant decrease in the expression of genes encoding regulators of intracellular membrane trafficking (Mss4 24, 25 and Pyy 26 , group 10, Table 1 ).
rhIL-11 Ameliorates Signs of Inflammatory Bowel Disease
The HLA-B27 rat develops inflammatory bowel disease that is clinically manifested as diarrhea and lesions in intestinal tissues. We have shown previously that HLA-B27 rats receiving two doses of rhIL-11 (37.5 mg/kg), 48 h apart and killed 4 h after the last dose had improved stool character, exhibited by increased number of days of normal stool character relative to number of days of diarrhea. 3 In the present study, the majority of the rhIL-11-treated HLA-B27 rats exhibited a change from diarrhea to normal stool as early as the first day (24 h) after receiving rhIL-11 (data not shown). Each rhIL-11-treated animal exhibited normal stool character on the day of killing. In contrast, no vehicletreated animal had normal stool character at any day during the study.
Histological analysis was performed on tissue isolated at both sacrificial time points. rhIL-11 treatment significantly reduced the total colonic lesion score compared to vehicletreated rats at both time points (Table 2 ). There were Table 1 . The genes were grouped into 22 clusters according to their relatedness and function. The functional categories are listed in the box and are linked to a color code. The genes comprising a category are shown by the same color.
significant differences in the level of ulceration and inflammation in the colon of the vehicle-treated HLA-B27 rats at the two sacrificial time points. However, the magnitude of the reduction in the levels of ulceration and inflammation induced by rhIL-11 treatment was significantly greater than that seen in the comparison between the control animals. rhIL-11 treatment also significantly reduced the depth of the colonic lesions in the HLA-B27 rat. There was no significant difference in the level of fibrosis between the rhIL-11-treated animals and the day 2 vehicle-treated groups.
Effect of rhIL-11 on Gene Expression in the Inflamed and Non-inflamed Colon rhIL-11 treatment significantly modulated the expression of 27 disease-associated genes in the colonic tissue of HLA-B27 rats compared to vehicle-treated rats (Table 3) . rhIL-11 treatment up-regulated the expression of 21 of these genes. The majority of these genes encode proteins involved in protein and lipid metabolism. In addition, rhIL-11 treatment up-regulated the expression of two genes encoding integral-membrane proteins of secretory vesicles (GP-2 and Sip9). Five of the disease-related genes were decreased by rhIL-11 treatment, including the MHC class II-like beta chain RT1.DMb. When the levels of these genes were evaluated in the colons of non-diseased Fisher 344 rats, it was revealed that rhIL-11 treatment of the HLA-B27 rat returned the expression of these genes to the level seen in the non-diseased colon (Table 3) .
rhIL-11 treatment also modulated the expression of eight genes that were not identified as disease related (not found to be significantly different in the Fischer 344 and vehicle-treated HLA-B27 comparison) ( Table 4) . Four genes were up-regulated by rhIL-11 treatment and encode known or putative growth factors of intestinal epithelial cells. The most highly induced genes (430-fold) encode two members of the Reg gene superfamily, 27 the Regeneration 1 (Reg1) and Regeneration III (RegIII) proteins. Spasmolytic peptide (TFF-2) and insulin II (Ins2) [28] [29] [30] [31] were also induced in the HLA-B27 rat in response to rhIL-11 treatment, although at a much lower frequency, 3.2-fold and 2.5-fold, respectively. Four genes were reduced by rhIL-11 treatment in the rhIL-11-responsive gene list (Table 4) . In comparison, rhIL-11 treatment of non-diseased Fischer rats resulted in very limited effects in colonic gene expression. Only three genes were modulated significantly by rhIL-11 treatment in the colons of Fischer 344 rats (Table 5) . These genes are all members of the rat L1 retrotransposon family (reviewed in Ostertag and Kazazian 32 ). rhIL-11 treatment of Fischer 344 rats did not affect the expression of any of the genes shown to be modulated in the diseased colons of the HLA-B27 rat (data not shown).
Localization of Intestinal Epithelial Growth Factor Expression in vivo
In situ hybridization analysis was performed on colonic tissues isolated from rhIL-11-and vehicle-treated HLA-B27 rats to localize the expression pattern of the Reg1, RegIII, TFF-2 and Ins2 genes. Signal for the presence of each gene was seen in the colonic biopsies isolated from rhIL-11-treated HLA-B27 rats (Figure 2a-d) . There was no signal detected in colonic tissue isolated from vehicle-treated HLA-B27 rats (Figure 2e-h) . These results support both the GeneChip s and RT-PCR results showing the absence of message for each of the four intestinal epithelial growth factors in the colon of vehicle-treated HLA-B27 rats. The expression pattern of all four genes in the colon of rhIL-11-treated HLA-B27 rats was essentially similar. Expression was localized to the cytoplasm of epithelial cells. Each gene was expressed in the cytoplasm of epithelial cells ranging from the bottom of the crypt to the luminal surface in longitudinally oriented colon sections (Figure 2a ) and in all the epithelial cells in the circumference of a cross-section through the crypts (Figure 2d ).
DISCUSSION
We have previously shown that rhIL-11 decreases the histological and clinical signs of IBD in the HLA-B27 rat and its activity is associated with the down-regulation a Three vehicle-treated and five rhIL-11-treated animals were killed at each time point after receiving two doses rhIL-11 (37.5 mg/kg) or vehicle (2 days treatment). The histological analysis was performed without prior knowledge of the sample type and scored as follows: ulceration 0-2, inflammation 0-3, lesion depth 0-3, and fibrosis 0-2. A score of 0 denotes no lesion.
of inflammatory cytokine expression and reduction of myeloperoxidase activity in affected intestinal tissue. 3 In the present study, we have extended our analysis of the molecular effects of rhIL-11 in this model by global expression analysis. The use of global expression analysis has allowed us to identify previously unrecognized The names and symbols of each gene are shown with a fold change value. Reg1, RegIII, TFF-2 and Ins2 were called absent in the vehicle-treated rat; therefore the fold change value for these genes is much larger than presented. a The names and symbols of 27 'disease-related' genes that rhIL-11 treatment specifically modulated are shown in columns one and two, respectively. The functional group in which the gene is classified in Table 1 is shown, along with the fold change modulation produced by rhIL-11 treatment of HLA-B27 rats (A) and the relative fold change in the non-diseased Fischer 344 colon compared to the vehicle-treated HLA-B27 rat colon (B). Significance was determined by a Student t-test and the resultant P values are shown. There were no significant differences between the rhIL-11 modulated levels of these genes in the HLA-B27 rat colon and their level in the non-diseased colon of the Fischer 344 control.
pathways in disease and rhIL-11 mechanism in this rat model of IBD. The Fischer 344 rat is the background strain for the transgeneic HLA-B27 rat and differs from the HLA-B27 rat only in the absence of the Human HLA-B27 and b2-microglobulin gene expression.
1 Therefore, we have defined gene expression differences between the Fischer 344 and HLA-B27 rat strains as disease related. This comparison allowed us to identify a gene set differentially expressed in the diseased colon associated with IBD in the HLA-B27 rat.
Chronic IBD in humans has been shown to be associated with increased class II MHC expression. 33 Studies have shown that the colonic epithelium of Crohn's disease patients develops strong expression of the HLA-DR antigen. [34] [35] [36] In our study, we found that RNA levels for the rat ortholog of the human HLA-DRB1 allele (RT1-Da1 and RTDb1) were significantly increased in the inflamed colon of the HLA-B27 rat. In addition, we found that expression of the rat MHC class II RT1-Bb and RT1-Ba alleles (orthologs of human HLA-DQB1 and HLA-DQA1, respectively) was also elevated in the HLA-B27 rat. Expression of the human ortholog of the rat RT-1B has been associated with genetic susceptibility to IBD in humans.
37-39 Therefore, we have correlated the expression of these class II MHC alleles with IBD in human disease and this rat model, suggestive of a related disease pathway.
Genes associated with the procession of antigens were upregulated in disease. These include four genes encoding individual proteosome subunits (Psmb2, 4, 8 and 9) and genes encoding the ABC transmembrane transporter molecules Abcb3 and Abcb1. MHC class I and II molecules were also up-regulated in the inflamed colon. These include the class II a and b chains (RT1-DMa and RT1-DMb 40 ) that are produced in association with a polypeptide derived from MHC class-II-associated invariant chain (Ii) to make functioning class II receptors. 41 A final step in the processing of class II receptors is the removal of a remnant of the Ii peptide (CLIP) in order to expose the antigen-binding site. Removal of the CLIP peptide is catalysed by the activity of the MHC class-II-like protein HLA-DM. 41 Consequently, we have identified increased expression of genes involved in antigen processing and assembly of MHC class II molecules in the inflamed colon of HLA-B27 rats. Increased expression of these genes as well as genes encoding T-cell receptors support the role of an aberrant immunological response in the colonic disease of this model. 18 Taken together, the expression profile suggests that enhanced or aberrant antigen processing is associated with disease in this model and is consistent with observations for human IBD.
We also detected increased expression of the mRNA encoding NFkB1, the P150 precursor of the P50 subunit of the nuclear factor NFkB. The P150 subunit of NFkB does not bind DNA; however, it contains the P50 subunit of NFkB which binds to the kB consensus sequence located in the enhancer region of inflammatory genes including TNFa, IL-1b, IL-12p40, IL-6 and inducible nitric oxide synthase (iNOS). We have shown in our previous work 3 that the colon of the HLA-B27 rat exhibits increased expression of the mRNA encoding these inflammatory cytokines, presumably resultant from increased NFkB activity. We also detected increased expression of the mRNA encoding Stat1, which plays an important role in IFNg-regulated gene expression (reviewed in Ramana et al 42 ) . Therefore, global expression analysis detected expression of the major transcription factors involved in the production of an inflammatory response and presumably the transcription factors responsible for the increased expression of inflammatory cytokines observed in the HLA-B27 colon.
The utility of animal models is the ability to conduct pharmacogenomic studies to elucidate the effects of drug treatment on gene expression in the appropriate target tissues. Changes in gene expression associated with drug efficacy can serve to identify genes and processes that may be involved in therapeutic mechanism. In our previous study, 3 we showed that splenocytes isolated from HLA-B27 rats treated with rhIL-11 produced significantly less IL-2, IL1b and IFNg when stimulated with anti-CD3 in vitro than vehicle-treated HLA-B27 rats. We suggested that rhIL-11 could potentially be modulating the activity of antigenpresenting cells. In this study, we show that rhIL-11 treatment of HLA-B27 rats resulted in reduced levels of mRNA encoding the beta chain of the RT1.DM 4.05-fold compared to the vehicle-treated HLA-B27 rats (RT1.DMb, Table 3 ). This was the only gene involved in antigen presentation or processing that was affected by rhIL-11 treatment. Moreover, the function of HLA-BM is critical for class II antigen presentation. Antigen-presenting cells deficient in HLA-DMb chain expression 43, 44 are defective in presenting antigen to T cells due to CLIP peptide occupation The names and symbols of each gene modulated by rhIL-11 treatment in the colon of Fischer 344 rats are shown in columns one and two, respectively. The GeneBank accession number along with the fold change (Fold D) modulation by rhIL-11 treatment is shown.
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of the antigen-binding site of class II MHC proteins. 45 We propose that the 4.05-fold reduction in RT1.DMb in the rhIL-11-treated HLA-B27 rat affects a key step in the antigen presentation pathway and may modulate antigen presentation in the colon. Therefore, a possible mechanism for disease amelioration by rhIL-11 may be a reduction in Figure 2 Reg1, RegIII, TFF-2 and Ins2 are expressed in colonic epithelial cells of HLA-B27 rats in response to rhIL-11 treatment. Reg1, RegIII, TFF-2 and Ins2 mRNA expression was investigated by in situ hybridization on colonic tissue isolated from vehicle-and rhIL-11-treated HLA-B27 rats. Digoxigenin-labeled sense and antisense probes were generated for each gene and were hybridized on colonic sections of rhIL-11-and vehicle-treated HLA-B27 rats. The antisense probe specifically recognized the mRNA of each target gene in the rhIL-11-treated animals, producing a brown stain in the cytoplasm of the epithelial cells in which it hybridized (Reg1 (a), RegIII (b), Ins2 (c) and TFF-2 (d)). Hybridization of colonic tissue isolated from vehicle-treated HLA-B27 rats with antisense probes did not detect expression of any of the four genes (e-h). Sense probe did not hybridize to colonic tissue isolated from rhIL-11-treated HLA-B27 rat (i-l) or vehicle-treated HLA-B27 rats (not shown). These results confirm that rhIL-11 induces the expression of intestinal epithelial cell growth factors in colonic epithelial cells.
antigen presentation leading to a reduced T-cell response in the colon.
This result supports the hypothesis that the pathogenic mechanism of the HLA-B27 allele is potentially mediated by presentation of antigen. Various studies have shown that HLA-B27 rats raised in a germ-free environment do not exhibit disease. Rath et al 46 showed that colonization of the intestinal tract of HLA-B27 rats raised in a germ-free environment with luminal bacteria, especially of the Bacteroides species, was sufficient to induce IBD. There was also a concomitant increase in the expression of proinflammatory cytokines in the colon of these animals. Presumably, the HLA-B27 allele recognizes an antigen of bacterial origin that is the key to the pathology. In order for the pathology to occur, antigen presentation via the HLA-B27 allele would have to occur. If, however, there was a defect in the processing of MHC class II molecules, as we propose is induced by rhIL-11 treatment, antigen processing would not be able to occur. Therefore, the amelioration of the IBD in the HLA-B27 by rhIL-11 suggests that blocking of MHC class II presentation is sufficient to block disease pathogenesis similar to raising HLA-B27 rats in a germ-free environment which inhibits IBD by mitigating exposure to the bacterial antigen.
By far the most striking differential expression associated with disease was the reduced expression of gene sets involved in the metabolism of proteins and lipids. The widespread down-regulation of these genes in the inflamed colon is indicative of a major disruption in metabolism and energy utilization in IBD. A similar decrease in the expression of genes associated with the metabolism of protein, lipid and carbohydrate has also been reported in colonic tissue isolated from ulcerative colitis (UC) patients. 34 Roediger initially suggested that the colonic epithelium of UC was an energy-deficient tissue based upon in vitro studies of colonocytes isolated from UC patients. 47 We found reductions in the expression of genes encoding proteins associated with phospholipid metabolism (Pnlip, Cel, Pnliprp2, Pla2g1b, Clps, Scd2, Fabp5) and fatty acid-b oxidation (Hmgcs2, Ratacoa1 and Cytb) and a significant increase in the expression of two genes (Hk2 and Pfkp), encoding major proteins controlling glucose metabolism. Treatment of HLA-B27 rats with rhIL-11 restored the expression levels of many genes encoding metabolic proteins to the expression level seen in a non-diseased colon. Our profiling study suggests that restoration of normal metabolic processes is associated with the amelioration of IBD and provides evidence for a role of metabolic deficiency in disease pathogenesis.
Many of these metabolic genes up-regulated by rhIL-11 treatment encode secreted proteins that must be processed and packaged in secretory vesicles for export from the cell. Two genes that were up-regulated by rhIL-11 treatment of the HLA-B27 rat have been shown to be integral-membrane proteins specifically incorporated into the membranes of secretory vesicles. Syncollin (Sip9) and the zymogen granule membrane protein (GP-2) are both described as integralmembrane proteins of pancreatic zymogen granules, the secretory vesicles of the pancreas. 19, 21 Sip9 is up-regulated 104.92-fold and GP-2 19.5-fold by rhIL-11 treatment in HLA-B27 rat colons compared to vehicle-treated HLA-B27 rats. Sip9 expression has also previously been detected in rat colon, as well as in the spleen and duodenum. 47 Sip9 possibly regulates the control of secretory vesicles translocation in a Ca 2+ -mediated process. 20 Its expression in the duodenum is increased in response to feeding, suggesting a role for Sip9 in the secretion of digestive enzymes. 48 GP-2 is the major protein of the pancreatic zymogen granule membrane and is localized to the apical membrane of pancreatic ancinar cells. 21 In vitro experiments have shown that both Sip9 and GP-2 localize to the membrane of secretory granules containing Amy2 in AtT20 cells. 22, 49 Therefore, rhIL-11 restores the levels of mRNA encoding metabolic proteins, which are exported from the cell in secretory vesicles, and proteins that localize in the membrane of secretory vesicles. This result implies that rhIL-11 restores the exocytotic process of epithelial cells, which is indicative of a healing or restorative response.
Various in vivo studies have indicated that rhIL-11 treatment promotes the growth of epithelial cells. Orazi et al 15 reported that rhIL-11 treatment of mice after cytoablative therapy with 5-FU and radiation resulted in rapid intestinal epithelium recovery mediated by increased mitotic activity of crypt cells. In rat models of short bowel resection surgery, rhIL-11 enhances crypt cell mitotic rates and increased mucosal mass. 16 ,50,51 rhIL-11 treatment of HLA-B27 rats results in the up-regulation of expression of four genes that may mediate proliferative effects. Two genes are members of the Reg gene superfamily 27 that were originally identified as potential growth factors for pancreatic islet cells. 52 However, Reg1 expression has also been detected in organs other than the pancreas, including normal gastrointestinal mucosa. 53 Reg1 gene expression is reported to increase during the healing of damaged gastric mucosa, specifically in enterochromaffin-like (ECL) cells. 54 Gastrin has long been known as a tropic factor of gastric mucosa. 55 Gastrin stimulates the production of Reg1 protein in ECL cells, linking the expression of Reg1 protein to the ability of gastrin to induce proliferation of mucosal cells. 56 This result supports the role of Reg1 gene in healing of gastrointestinal mucosal lesions. 57 RegIII is also a member of the Reg gene family. 27 Members of the RegIII subclass have been shown to be expressed in normal Paneth cells of the human gastrointestinal tract.
58
TFF2 is a member of the trefoil peptide family, which are major secretory products of mucus cells of the gastrointestinal tract that show increased expression at sites of mucosal injury. 59, 60 TFF2 is expressed within 30 min following mucosal damage 61 and has been shown to stimulate cell migration in vitro. 59 One of the earliest processes following mucosal injury is a rapid migration of cells from the margins of the damaged region over the denuded area to re-establish epithelial integrity. 59 These results suggest that TFF2 is an important mediator of the migration of epithelial cells to heal intestinal lesions. Orally administered recombinant TFF2 has been effective in treating aspirin-induced gastric injury when administered before or concomitantly with aspirin. 62 Tran et al 63 found that TFF2 is negligibly expressed in the normal colon but endogenous concentrations of TFF2 protein increased following dinitrobenzene sulfonic acid (DNB)-induced injury. Orally administered rhTFF2 in this model accelerated healing and reduced the levels of myeloperoxidase activity in the colon. The induction of TFF2 expression by rhIL-11 in the HLA-B27-treated rat may contribute to the observed reduction of myeloperoxidase activity seen in our previous study as well as enhanced lesion healing. 3 The role of these growth factors in epithelial growth and restoration and their induction during amelioration of disease suggests their possible therapeutic use to induce healing of the lesions of IBD.
We did not detect increased expression of Reg1, RegIII, TFF2 or Ins2 over significant levels in the colon of rhIL-11-treated Fischer 344 rats. Our results therefore suggest that treatment of normal rats with rhIL-11 has little effect and suggests that an inflamed or damaged colon is more responsive to rhIL-11 treatment. Therefore, the effects of rhIL-11 in the HLA-B27 colon may potentially be mediated in synergy with factors present in the damaged but not normal intestine and potentially responsive to the anti-inflammatory properties of rhIL-11. However, expression of Reg family members has been detected in the inflamed tissues isolated from Crohn's disease and ulcerative colitis without drug treatment and have been suggested to be markers of disease. 34 This discrepancy between our results leads us to speculate that the colitis in these animals is much more severe than the human disease. The interpretation of our results then would suggest that the expression of Reg1 in the colons of Crohn's disease patients is evidence of a reparative process and not strictly a marker of disease.
In summary, we have shown that the inflammatory bowel disease in the HLA-B27 rat is associated with increased expression of gene sets associated with antigen processing and presentation, an inflammatory response, cell death and T-cell receptors. This molecular data is supportive of previous studies conducted to define the mechanism of disease in this animal. 1, 18, [64] [65] [66] [67] From our global expression analysis, we have identified a widespread down-regulation of genes associated with metabolism and energy utilization in the colon of the HLA-B27 rat. Expression profiling revealed the association of multiple mechanisms in the amelioration of disease induced by rhIL-11 therapy. rhIL-11 caused a reduction in the expression of inflammatory cytokines, presumably through its ability to inhibit the nuclear translocation of the transcription factor NFkB. 7 We propose that rhIL-11 further modulates the immunological response by reducing class II antigen presentation through reduction of RT1.DMb expression. Taken together, these effects of rhIL-11 treatment cause a reduction in the immune response in the HLA-B27 colon. In addition to immune modulation, rhIL-11 mediates epithelial restoration through the up-regulation of four epithelial growth factors associated with proliferation of epithelial cells that restore membrane integrity. The expression profile also indicates that normal metabolic activity is restored by normalization of RNA levels for multiple genes involved with metabolism and energy utilization. Mechanistically, this leads to healing of the epithelium, decreased fluid loss from the colonic mucosa and normalization of the stool character.
We feel that this study has shown the utility and value of pharmacogenomic studies in an animal model to identify disease-related and drug-responsive genes to provide possible pathways of drug action.
MATERIALS AND METHODS
Experimental Design
Male transgenic rats engineered to over-express the human MHC class I allele HLA-B27 and b2-microglobulin genes on a Fischer 344 background were obtained from Taconic (Germantown, New York, USA). Rats in this study were between the ages of 22 and 28 weeks when IBD was evident based on the presence of diarrhea or soft stool character. Age-matched male Fischer 344 rats were also obtained from Taconic. rhIL-11 (specific activity 1.5 Â 10 6 U/mg) was manufactured at Genetics Institute. Rats received 37.5 mg/kg rhIL-11 or vehicle subcutaneously at time 0 and 48 h. Three vehicle-treated HLA-B27 rats and five rhIL-11-treated HLA-B27 rats were killed 4 and 24 h after the second dose of rhIL-11. Fischer 344 rats received 37.5 mg rhIL-11 or vehicle subcutaneously at time 0 and 48 h, and an intraperitoneal injection of 500 mg/kg BrdU at the second time point (48 h). Five rhIL-11-treated Fischer 344 rats and five vehicle-treated rats were killed 4 h after the vehicle/BrdU or rhIL-11 dose. These animals represented normal or non-diseased tissue. The HLA-B27 rats were observed daily for stool character and characterized as normal, soft or diarrhea as previously described. 23 After the rats were killed, sections of the colon were removed in a standardized manner described previously to insure that the same regions of the colon were represented in both the gene expression and histological analysis. 2, 3 Tissue obtained for histological, immunohistological and in situ analysis was rinsed in ice-cold phosphate-buffered saline (PBS) and then fixed for 24 h in 10% neutral-buffered formalin. The remaining portion of the tissue was rinsed in ice-cold PBS and snap frozen in liquid nitrogen for use in RNA preparation.
Histological Evaluation
Hematoxylin-and eosin-stained 5 mM tissue sections were evaluated without the knowledge of the treatment group and scored using a scale modified after BoughtonSmith. 3, 68, 69 After scoring, the samples were unblinded and data were combined, tabulated and analysed by ANOVA linear modeling (Abacus Concepts, Berkeley, CA, USA) with multiple mean comparisons. Differences between the group means were considered significant if Po0.05. The criteria for scoring the histology have been described previously. 68 
RNA Extraction
Frozen colonic tissue from individual rats was pulverized using a mortar and pestle cooled in liquid nitrogen. Total RNA was prepared using the RNAgent Total RNA Isolation kit (Promega, Madison, WI, USA) following the manufacturer's protocol.
Hybridization of cRNA to Oligonucleotide Arrays
The Affymetrix RG_U34A rat GeneChips (Affymetrix, Santa Clara, CA) were used in expression profile studies. The RG_U34A chip contains probes derived from all full-length or annotated rat sequence from Build #34 of the UniGene Database (created from Genbank 107/dbEST 11/18/98) and supplemented with additional annotated gene sequences from Genbank 110 as well as EST sequences (www.affymetrix.com). Total RNA (10 mg) was converted to biotinylated cRNA according to the Affymetrix protocol. Eleven control transcripts ranging in abundance from 1:300 000 (or 3 ppm) to 1:100 (or 100 ppm) were spiked into each sample prior to the in vitro transcription reaction to act as a standard curve used to normalize hybridization data between chips. 70 The biotinylated cRNA was purified using an RNeasy spin column (Qiagen) and quantitated using a spectrophotometer. Labeled cRNA (15 mg) was fragmented in a 40 ul volume-nm containing 40 mM Trisacetate pH 8.0, 100 nm KOAc, 30 nm MgOAc for 35 min at 94 o C. The fragmented cRNA was diluted in 1 Â MES buffer containing 100 mg/ml herring sperm DNA and 50 mg/ml acetylated BSA (Gibco) and denatured for 5 min at 991C followed immediately by 5 min at 451C. Insoluble material was removed by a brief centrifugation and the hybridization mix was added to each array and incubated at 451C for 16 h with continuous rotation at 60 rpm. After incubation, the hybridization mix was removed and the chips were extensively washed as described in the Affymetrix protocol.
GeneChip
s Data Analysis The raw fluorescent intensity value of each gene was measured at a resolution of 6 mm with a Hewlett-Packard Gene Array Scanner. GeneChip s software 3.2 (Affymetrix), which uses an algorithm to determine if a gene is 'present' or 'absent' as well as the specific hybridization intensity values or 'average differences' of each gene on the array, was used to evaluate the fluorescent data. The average difference for each gene was normalized to frequency values by referral to the average differences of the 11 control transcripts of known abundance that were spiked into each hybridization mix according to the procedure of Hill et al. 70 The frequency of each gene was calculated and represents a value equal to the total number of individual gene transcripts per 10 6 total transcripts. The frequency of each gene was evaluated and the gene was included in the study if it met the following criteria. Genes that were called 'present' by the GeneChip s software in at least 60% of the arrays comprising one or more groups were included in the analysis (3365 genes met this criteria in the Fischer 344 vs HLA-B27 rat comparison and 3064 met this criteria in the HLA-B27 vs rhIL-11-treated HLA-B27 rat comparison).
Secondly, for comparison between treatment groups, a ttest was applied to identify the subset of genes that had a significant (Po0.05) increase or decrease in frequency values. Thirdly, average fold changes in frequency values across the statistically significant subset of genes were required to be 2.4-fold or greater. Fourthly, frequency values for a gene considered to be statistically significant were required to be above 10 in 60% of the animals in one or more groups (175 genes met this criteria in the Fischer 344 vs HLA-B27 rat comparison and 35 genes met this criteria in the HLA-B27 vs rhIL-11-treated HLA-B27 rat comparison). These criteria were established based upon replicate experiments that estimated the intra-array reproducibility (data not shown).
Using LocusLink and Unigene to Assign Gene Content to Probe Sets on the RG_U34A Affymetrix GeneChips One of the current limitations for the annotation of rat genes is that relatively few numbers of rat genes have been curated compared to mouse and human. LocusLink is a compendium of gene sequences submitted to GeneBank that are representative of the same gene in five species (orthologous sequences). This grouping and classification provides a single query interface of curated sequences providing descriptive information about genetic function and loci. To supplement the available gene information for rats, we used a simple BLAST screen to acquire gene information for the RG_U34A rat GeneChip s array from orthologous sequences present on the human HuGeneFL, and murine Mu11KsubA and Mu11KsubB Affymetrix GeneChip s arrays. The complete sequence records relating to specific target sequences for the human HuGeneFL, and murine Mu1-1KsubA and Mu11KsubB Affymetrix GeneChip s arrays were compiled into species-specific sets. A BLASTN was performed for each target sequence against each of the two complete sequence collections from dissimilar species to assist in identifying orthologs. All target sequences from the RG_U34A array were BLASTed against the complete sequence collections for both the mouse and human arrays identified above. The results were then used to provide a quick screen for orthologous sequences.
Given a target sequence on the RG_U34A array, the top BLAST hit from the mouse complete sequence collection was identified. The BLAST result for the target sequence of this top hit against the rat complete sequence set was then examined. If the top BLAST hit of this search yielded the complete sequence related to the original rat target sequence, this was identified as a reciprocal BLAST hit and given an appropriate evidence score. Additionally, an evidence score was assigned based on the e-value of the original BLAST result. This procedure was also performed against the human complete sequence collection. The result of these screens was a summed evidence score. If the score for an associated human or mouse sequence was of sufficient value, the rat sequence was identified as being orthologous to that human or mouse sequence, and gene content information was shared among the orthologous sequences. If the evidence score was not of sufficient value, more involved sequence analysis was performed to attempt to identify orthologous sequences.
cRNA Probe Generation and in situ Hybridization DNA fragments to serve as templates for generation of in situ hybridization probes were amplified from colonic RNA isolated from an rhIL-11-treated HLA-B27 rat using RT-PCR. Total RNA was DNAse treated for 30 min at 37 o C using 10 U/ ml RQ1 RNAse-free DNAse (Promega) to remove contaminating DNA. The DNAse was removed and the total RNA purified using an RNeasy spin column (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. Total RNA (1 mg) was reverse transcribed (RT) using the GeneAmp RT-PCR kit (Perkin Elmer, Norwalk, CT, USA) and random hexamers according to the manufacturer's protocol. Onetenth of the RT reaction volume was subjected to 40 cycles of amplification using gene-specific oligos and the Opti- Amplified DNA fragments were purified from 4% agarose gels using the Qiaquick Gel extraction kit (Qiagen) and used as template to generate sense and antisense cRNA probes using the Maxiscipt T3/T7 kit (Ambion, Austin, TX, USA) and digoxigenin-11-uridine-5 0 -triphosphate (Roche Diagnostics, Indianapolis, IN, USA) as the labeling nucleotide. The labeled probes were then used for in situ hybridization experiments using a protocol previously described. 71 
